Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Bionano Genomics
BNGO
Bionano Genomics
Operating Losses Will Curb Genomics Progress Yet Kindle Modest Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
19 Aug 25
Updated
19 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$8.00
59.1% undervalued
intrinsic discount
19 Aug
US$3.27
Loading
1Y
-89.5%
7D
6.2%
Author's Valuation
US$8.0
59.1% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$8.0
59.1% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-227m
122m
2016
2018
2020
2022
2024
2025
2026
2028
Revenue US$121.7m
Earnings US$15.6m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
24.19%
Life Sciences revenue growth rate
0.32%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
9.78%
Calculation
US$15.58m
Earnings '28
x
6.99x
PE Ratio '28
=
US$108.85m
Market Cap '28
US$108.85m
Market Cap '28
/
10.28m
No. shares '28
=
US$10.58
Share Price '28
US$10.58
Share Price '28
Discounted to 2025 @ 9.78% p.a.
=
US$8.00
Fair Value '25
